APYX Overview

Apyx Medical, Inc., formerly Apyx Medical Corporation, is a surgical aesthetics company. Its segments include Advanced Energy and Original Equipment Manufacturer (OEM). The Advanced Energy segment’s product portfolio consists of its Helium Plasma Technology that is marketed and sold as Renuvion in the cosmetic surgery market and J-Plasma in the hospital surgical market. It focuses on the cosmetic surgery market, where Renuvion offers plastic surgeons, facial plastic surgeons and cosmetic physicians the ability to provide controlled heat to the tissue to achieve their desired results. These product lines consist of a multifunction generator, a handpiece and a supply of helium gas. Through OEM agreements, the OEM segment, designs, develops and manufactures electrosurgical equipment and medical devices by producing generators, medical devices and related accessories for medical device manufacturers as well as start-up businesses in need of its energy-based designs.

Wall Street analysts forecast APYX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for APYX is7.00 USD with a low forecast of 6.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Apyx Medical Inc revenue for the last quarter amounts to 19.16M USD, increased 34.75

Apyx Medical Inc. EPS for the last quarter amounts to -0.03 USD, decreased -75.00

Apyx Medical Inc (APYX) has 205 emplpoyees as of March 25 2026.

Today APYX has the market capitalization of 164.81M USD.